

Financial Tear Sheet

Corporate Profile

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187[®], a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the recent Settlement and License Agreement and received from Biogen a non-refundable cash fee of \$1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera[®] or other DMF products for MS, dependent on, among other things, successfully appealing the U.S. interference and a favorable outcome in Europe with respect to the EP2801355 Opposition Proceedings, including any appeal thereto.

Stock Performance

FWP (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Financial Status Indicator	C
Price	\$2.71
Change (%)	▼ 0.02 (0.73%)
Volume	7,357
52 Week Low	\$1.64
Market Cap	\$255,737,275
Rolling EPS	3.66
PE Ratio	0.7456
Shares Outstanding	94,367,998

Data as of 07/20/18 4:00 p.m. ET



Recent Headlines

05/07/18

Forward Pharma Appeals the Decision of the Opposition Division to Revoke the EP2801355 Patent

04/30/18

Forward Pharma Reports Full-Year 2017 Financial and Operational Results

02/07/18

Forward Pharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
05/30/18	6-K
05/07/18	6-K
05/04/18	SC 13G/A
05/01/18	6-K

Corporate Governance

Claus Bo Svendsen, MD, PhD	CEO
Peder Møller Andersen, MD	COO

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources